From bench to bedside: the past, present and future of IL-21 immunotherapy
Medical Oncology · 2024
DOI: 10.1007/s12032-024-02404-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2024. Verfasst von Austin M Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, Des Moines, IA, 50312, USA. Hauptthemen laut MEDLINE: Interleukins, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, Des Moines, IA, 50312, USA.
- The Department of Respiratory Medicine, The 2nd People's Hospital of Hefei and Hefei Hospital Affiliated to Anhui Medical University, Hefei, China.
- Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA.
- Department of Microbiology, Immunology & Pathology, Des Moines University College of Osteopathic Medicine, Des Moines, IA, 50312, USA. yujiang.fang@dmu.edu.
- Department of Surgery, University of Missouri School of Medicine, Columbia, MO, 65212, USA. yujiang.fang@dmu.edu.
Zitieren
APA
Kim, A. M., Zhao, L., Patel, T. R., Bailey, C. J., Bai, Q., Wakefield, M. R., & Fang, Y. (2024). From bench to bedside: the past, present and future of IL-21 immunotherapy. Medical Oncology. https://doi.org/10.1007/s12032-024-02404-7
Vancouver
Kim AM, Zhao L, Patel TR, Bailey CJ, Bai Q, Wakefield MR, et al. From bench to bedside: the past, present and future of IL-21 immunotherapy. Medical Oncology. 2024. doi:10.1007/s12032-024-02404-7
BibTeX
@article{Kim2024,
author = {Kim, Austin M and Zhao, Lei and Patel, Tej R and Bailey, Colin J and Bai, Qian and Wakefield, Mark R and Fang, Yujiang},
title = {From bench to bedside: the past, present and future of IL-21 immunotherapy},
journal = {Medical Oncology},
year = {2024},
doi = {10.1007/s12032-024-02404-7}
}
EUVIMED